Logo image of APGE

APOGEE THERAPEUTICS INC (APGE) Stock Fundamental Analysis

NASDAQ:APGE - Nasdaq - US03770N1019 - Common Stock - Currency: USD

36.85  -0.2 (-0.54%)

After market: 36.85 0 (0%)

Fundamental Rating

3

APGE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for APGE as it has an excellent financial health rating, but there are worries on the profitability. APGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

APGE had negative earnings in the past year.
APGE had a negative operating cash flow in the past year.
APGE Yearly Net Income VS EBIT VS OCF VS FCFAPGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

APGE has a Return On Assets of -24.16%. This is in the better half of the industry: APGE outperforms 73.59% of its industry peers.
Looking at the Return On Equity, with a value of -25.41%, APGE belongs to the top of the industry, outperforming 82.39% of the companies in the same industry.
Industry RankSector Rank
ROA -24.16%
ROE -25.41%
ROIC N/A
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APGE Yearly ROA, ROE, ROICAPGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APGE Yearly Profit, Operating, Gross MarginsAPGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, APGE has more shares outstanding
There is no outstanding debt for APGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APGE Yearly Shares OutstandingAPGE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
APGE Yearly Total Debt VS Total AssetsAPGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M

2.2 Solvency

APGE has an Altman-Z score of 34.88. This indicates that APGE is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 34.88, APGE belongs to the best of the industry, outperforming 97.71% of the companies in the same industry.
APGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.88
ROIC/WACCN/A
WACCN/A
APGE Yearly LT Debt VS Equity VS FCFAPGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 18.55 indicates that APGE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 18.55, APGE belongs to the top of the industry, outperforming 93.66% of the companies in the same industry.
A Quick Ratio of 18.55 indicates that APGE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 18.55, APGE belongs to the top of the industry, outperforming 93.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.55
Quick Ratio 18.55
APGE Yearly Current Assets VS Current LiabilitesAPGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for APGE have decreased strongly by -85.39% in the last year.
EPS 1Y (TTM)-85.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

APGE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-55.71%
EPS Next 2Y-36.64%
EPS Next 3Y-26.18%
EPS Next 5Y-13.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APGE Yearly Revenue VS EstimatesAPGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 1B 2B 3B
APGE Yearly EPS VS EstimatesAPGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APGE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APGE Price Earnings VS Forward Price EarningsAPGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APGE Per share dataAPGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A cheap valuation may be justified as APGE's earnings are expected to decrease with -26.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.64%
EPS Next 3Y-26.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APOGEE THERAPEUTICS INC

NASDAQ:APGE (4/25/2025, 8:00:00 PM)

After market: 36.85 0 (0%)

36.85

-0.2 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners129.51%
Inst Owner Change0%
Ins Owners1.76%
Ins Owner Change-3.76%
Market Cap2.19B
Analysts90
Price Target95.37 (158.81%)
Short Float %21.72%
Short Ratio11.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.72%
Min EPS beat(2)-9.03%
Max EPS beat(2)-8.41%
EPS beat(4)1
Avg EPS beat(4)-4.33%
Min EPS beat(4)-9.03%
Max EPS beat(4)2.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.32%
PT rev (3m)1.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.44%
EPS NY rev (1m)-16.15%
EPS NY rev (3m)-16.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.06
P/tB 3.06
EV/EBITDA N/A
EPS(TTM)-3.29
EYN/A
EPS(NY)-5.12
Fwd EYN/A
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS0
BVpS12.05
TBVpS12.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.16%
ROE -25.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.75%
ROA(5y)N/A
ROE(3y)-25.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 609.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.55
Quick Ratio 18.55
Altman-Z 34.88
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.87%
EPS Next Y-55.71%
EPS Next 2Y-36.64%
EPS Next 3Y-26.18%
EPS Next 5Y-13.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-133.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.34%
EBIT Next 3Y-24.62%
EBIT Next 5YN/A
FCF growth 1Y-129.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-128.96%
OCF growth 3YN/A
OCF growth 5YN/A